Brain tumor research and treatment最新文献_第10页

Digital Pathology and Artificial Intelligence Applications in Pathology 数字病理学和人工智能在病理学中的应用

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2021.0032

H. Go

{"title":"Digital Pathology and Artificial Intelligence Applications in Pathology","authors":"H. Go","doi":"10.14791/btrt.2021.0032","DOIUrl":"https://doi.org/10.14791/btrt.2021.0032","url":null,"abstract":"Digital pathology is revolutionizing pathology. The introduction of digital pathology made it possible to comprehensively change the pathology diagnosis workflow, apply and develop pathological artificial intelligence (AI) models, generate pathological big data, and perform telepathology. AI algorithms, including machine learning and deep learning, are used for the detection, segmentation, registration, processing, and classification of digitized pathological images. Pathological AI algorithms can be helpfully utilized for diagnostic screening, morphometric analysis of biomarkers, the discovery of new meanings of prognosis and therapeutic response in pathological images, and improvement of diagnostic efficiency. In order to develop a successful pathological AI model, it is necessary to consider the selection of a suitable type of image for a subject, utilization of big data repositories, the setting of an effective annotation strategy, image standardization, and color normalization. This review will elaborate on the advantages and perspectives of digital pathology, AI-based approaches, the applications in pathology, and considerations and challenges in the development of pathological AI models.","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43305055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Peripheral T-Cell Lymphoma Presenting as a Scalp Mass. 外周t细胞淋巴瘤表现为头皮肿块。

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2022.0004

Moo Seong Kim, Se Young Pyo, Ha Young Park, Hyuck Rae Jo, Jeongeun Kim

{"title":"Peripheral T-Cell Lymphoma Presenting as a Scalp Mass.","authors":"Moo Seong Kim, Se Young Pyo, Ha Young Park, Hyuck Rae Jo, Jeongeun Kim","doi":"10.14791/btrt.2022.0004","DOIUrl":"https://doi.org/10.14791/btrt.2022.0004","url":null,"abstract":"Peripheral scalp T-cell lymphoma is a very rare disease. We report a case of a 22-year-old man who presented an indolent large scalp mass in the right frontal scalp region. The patient's physical examination demonstrated no palpable mass in the chest, abdomen, and extremities. The brain CT revealed a high-density large scalp mass of the subgaleal layer in the right frontal and a small scalp mass of the subgaleal layer in the left frontal. The brain MRI showed multifocal enhancing masses in the bilateral dura, the subgaleal layer of the scalp, and the skull. The patient underwent removal of the tumor found in the right frontal scalp. The histologic diagnosis was peripheral T-cell lymphoma. Bone marrow aspiration showed the involvement of T-cell lymphoma. The patient received chemotherapy with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP protocol) for 3 cycles. The patient was discharged without neurological deficit. The patient showed no evidence of recurrence 15 months after surgery. We report a rare case of peripheral T-cell lymphoma mimicking benign scalp tumors.","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/56/btrt-10-113.PMC9098978.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Updates on Radiation Therapy for Pediatric Optic Pathway Glioma 放射治疗小儿视通路胶质瘤的最新进展

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2022.0003

N. Kim, D. Lim

引用次数: 5

Recent Update in Pharmacological Agents for Optic Pathway Glioma 光通路胶质瘤药物研究进展

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2022.0006

Meerim Park

引用次数: 0

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report 放疗与免疫联合治疗成人异柠檬酸脱氢酶突变脑干胶质瘤1例

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2022.0009

Takayuki Morimoto, R. Matsuda, T. Nakazawa, F. Nishimura, I. Nakagawa

引用次数: 1

The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO 由KSNO, NCCN和EANO提供的胶质瘤实用指南概述

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2022.0001

Young Zoon Kim, Chae-Yong Kim, D. Lim

{"title":"The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO","authors":"Young Zoon Kim, Chae-Yong Kim, D. Lim","doi":"10.14791/btrt.2022.0001","DOIUrl":"https://doi.org/10.14791/btrt.2022.0001","url":null,"abstract":"Gliomas have been histologically diagnosed as the third most common primary tumor of the central nervous system (CNS) in a relatively small portion of Korea. Despite the rarity of gliomas, the disease entity is very dynamic due to its various molecular characteristics, compared with other CNS tumors. The practice of managing glioma patients is not globally established as a precise standard guideline because of the different socio-medical environments of individual countries. The Korean Society for Neuro-Oncology (KSNO) published guidelines for managing adult glioma in 2019, and the National Comprehensive Cancer Network and European Association of Neuro-Oncology published guidelines in September 2021 and March 2021, respectively. However, these guidelines have several different recommendations in practice, including tissue management, adjuvant treatment after surgical resection, and salvage treatment for recurrent/progressive gliomas. Currently, the KSNO guideline working group is preparing an updated version of the guideline for managing adult gliomas. In this review, common features have been verified and different points are analyzed. Consequently, this review is expected to be informative and helpful to provide high quality evidence and a strong recommendation level for the establishment of new KSNO guidelines for managing gliomas.","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43221830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Recurrent L3 Chordoma Presented as Intradural Extramedullary Mass With Distant Metastasis: A Case Report 复发的L3脊索瘤表现为硬膜内髓外肿块伴远处转移1例

Brain tumor research and treatment Pub Date : 2022-04-01 DOI: 10.14791/btrt.2022.0007

S. Jang, Nayoung Han, E. K. Hong, H. Gwak

{"title":"Recurrent L3 Chordoma Presented as Intradural Extramedullary Mass With Distant Metastasis: A Case Report","authors":"S. Jang, Nayoung Han, E. K. Hong, H. Gwak","doi":"10.14791/btrt.2022.0007","DOIUrl":"https://doi.org/10.14791/btrt.2022.0007","url":null,"abstract":"Here, we report a rare case of L3 chordoma progressed to an intradural extramedullary (IDEM) mass and distant metastasis to the fascia lata. A 64-year old female patient presented to a local university hospital due to back pain and received excisional biopsy for a L3 destructive bony lesion. Local radiation therapy was initially administered, assuming a malignancy of unknown origin, but she developed cerebrospinal fluid leakage during adjuvant radiation therapy, which was managed by wound revision and lumbar drainage. As the destructive lesion progressed, she visited our hospital for a second opinion 3 months after the biopsy. After review of outside pathology, we diagnosed the lesion to be a chordoma, and performed a L3 corpectomy with cage and plate fixation. One and a half years later, positron emission tomography and computed tomography (PET-CT) revealed a right tensor fascia lata hypermetabolic lesion. Excisional biopsy confirmed a distant metastasis of the chordoma. One year later, she complained of L2 radiating pain. PET-CT and CT myelogram revealed an IDEM lesion. Surgical excision confirmed the transdural invasion of the chordoma. To our knowledge, this is the first report of an iatrogenic IDEM invasion and distant metastasis to the tensor of the fascia lata by a L3 chordoma.","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47762032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

WFNOS 2022 Abstract Book, March 24-27, 2022, Coex, Seoul, Korea. WFNOS 2022摘要书，2022年3月24-27日，韩国首尔Coex。

Brain tumor research and treatment Pub Date : 2022-03-01 DOI: 10.14791/btrt.2022.10.Suppl

引用次数: 0

Current Immunotherapeutic Approaches for Malignant Gliomas. 恶性胶质瘤的当前免疫治疗方法。

Brain tumor research and treatment Pub Date : 2022-01-01 DOI: 10.14791/btrt.2022.10.e25

Myung-Hoon Han, Choong Hyun Kim

{"title":"Current Immunotherapeutic Approaches for Malignant Gliomas.","authors":"Myung-Hoon Han, Choong Hyun Kim","doi":"10.14791/btrt.2022.10.e25","DOIUrl":"https://doi.org/10.14791/btrt.2022.10.e25","url":null,"abstract":"Glioblastoma is the most common malignant central nervous system (CNS) tumor (48.3%), with a median survival of only about 14.6 months. Although the CNS is an immune-privileged site, activated T cells can cross the blood-brain barrier. The recent successes of several immunotherapies for various cancers have drawn interest in immunotherapy for treatment of malignant glioma. There have been extensive attempts to evaluate the efficiency of immunotherapy against malignant glioma. Passive immunotherapy for malignant glioma includes monoclonal antibody-mediated immunotherapy, cytokine-mediated therapy, and adoptive cell transfer, also known as chimeric antigen receptor T cell treatment. On the other hand, active immunotherapy, which stimulates the patient's adaptive immune system against specific tumor-associated antigens, includes cancer vaccines that are divided into peptide vaccines and cell-based vaccines. In addition, there is immune checkpoint blockade therapy, which increases the efficiency of immunotherapy by reducing the resistance of malignant glioma to immunotherapy. Despite centuries of efforts, immunotherapeutic successes for malignant glioma remain limited. However, many clinical trials of adoptive cell transfer immunotherapy on malignant glioma are ongoing, and the outcomes are eagerly awaited. In addition, although there are still several obstacles, current clinical trials using personalized neoantigen-based dendritic cell vaccines offer new hope to glioblastoma patients. Furthermore, immune checkpoint targeted therapy is expected to decipher the mechanism of immunotherapy resistance in malignant glioma in the near future. More studies are needed to increase the efficacy of immunotherapy in malignant glioma. We hope that immunotherapy will become a new treatment of malignant glioma.","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/25/btrt-10-1.PMC8819466.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39888500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis. 脑室外神经细胞瘤:异质预后的临床研究。

Brain tumor research and treatment Pub Date : 2022-01-01 DOI: 10.14791/btrt.2022.10.e30

Joonho Byun, Moinay Kim, Sang Woo Song, Young-Hoon Kim, Chang Ki Hong, Jeong Hoon Kim

{"title":"Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis.","authors":"Joonho Byun, Moinay Kim, Sang Woo Song, Young-Hoon Kim, Chang Ki Hong, Jeong Hoon Kim","doi":"10.14791/btrt.2022.10.e30","DOIUrl":"https://doi.org/10.14791/btrt.2022.10.e30","url":null,"abstract":"Background: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN.Methods: A total of eight consecutive cases were enrolled and investigated. The prognosis of EVN was analyzed and compared to that of central neurocytoma (CN).Results: There were two male and six female patients, and the median age was 36.5 years. The median tumor size was 38 mm, and the most common location of the tumor was the frontal lobe (3, 37.5%), followed by the parietal and temporal lobes. In brain imaging, four (50%) tumors showed peritumoral edema and three (37.5%) tumors showed calcification. All patients underwent gross total resection, and two (25%) underwent adjuvant radiotherapy. The 5-year overall survival (OS) was 55.6%, and the 2-year progression-free survival (PFS) was 42.9%. The OS and PFS of EVN were poor compared to those of CN. Although EVN is a single disease entity, individual patients showed varying prognosis. One patient showed no recurrence during the 7-year follow-up period; however, another patient had a recurrence 4 months after surgery and died 2 years later.Conclusion: EVN may be a heterogenous disease entity. Additional cases with long-term followup are needed to develop optimal management protocols.","PeriodicalId":72453,"journal":{"name":"Brain tumor research and treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/66/btrt-10-22.PMC8819464.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39888501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3